#News: Editas Medicine to present clinical data from the RUBY and EdiTHAL trials of reni-cel at the European Hematology Association 2024 Congress in June. Read the press release for details: https://bit.ly/3WBoV0T #EHA2024 #geneediting #sicklecelldisease #thalassemia
Editas Medicine’s Post
More Relevant Posts
-
Regulatory Scientist | Cell & Gene Therapies | Process & Analytical Development | CMC | Immunology | Infectious Diseases | Biomarkers
Additional data release from UCART22 presented by Cellectis at the 2023 European Hematology Association (EHA). Impressive safety and (at least acutely) what appears to be very positive efficacy data seen in a HEAVILY pretreated population of an additional x6 B-cell ALL patients, with no dose limiting toxocities, no ICANS and managable levels of CRS. In the FCA-DL3 cohort, there was a 50% response rate (3/6 patients), and overall 28% (5/18) of patients achieved CR/CRi. UCART22 cell expansion was detected in 9/13 patients in the FCA LD arm, with expansion being associated with clinical activity. Very pleased to see a recent uptick in positive data releases from allogeneic cell therapy assets progressing through the pipeline. #allogeneic #celltherapy #cellandgenetherapy #leukemia #advancedtherapies
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA). To read the press release: https://lnkd.in/eJzanyRe #data #eha2023 #cellandgenetherapy
To view or add a comment, sign in
-
NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology
To view or add a comment, sign in
-
Can BCMA-Targeting therapies improve survival in patients with relapsed/recurring #MultipleMyeloma? Learn more at the Hematology Advisor Institute, and earn CME/CE. https://brnw.ch/21wBDVc
To view or add a comment, sign in
-
ISB 1342, Ichnos’ CD38 x CD3 T-cell engager for relapsed/refractory multiple myeloma, is highlighted on the cover of the American Society of Hematology's journal, Blood. In this latest print edition of the journal, you’ll find our latest research article, Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma: https://lnkd.in/ezwyFBUE
To view or add a comment, sign in
-
Greetings from EHA, one of the most important international congresses in hematology. We are here today to present the newest findings of our CONTINUATION-PV trial. This study was part of a clinical development program which has now been completed. Read the abstract here: https://lnkd.in/dX5JhFqA #aophealth #needssciencetrust #eha2023 #clinicalresearch
To view or add a comment, sign in
-
Welcome to a new hematology podcast! In this episode, we'll unravel the complexities of MGRS, kidney disorders related to monoclonal immunoglobulins. Our guest, dr. Amaryllis Van Craenenbroeck, Assistant Professor at UZ Leuven, is here to guide us. Let's begin! #MGRS
A new episode of the Hematology podcast is now published about MGRS - Monoclonal gammopathy of renal significance. MGRS is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD).
MGRS- Monoclonal Gammopathy of Renal Significance - The Hematology Podcast
buzzsprout.com
To view or add a comment, sign in
-
Molecular Biologist, MSc. | PhD in progress | Developing Liquid Biopsy-based Cancer Diagnostics | Genetics, WGS, WES, Clinical Research
What is the value of plasma cfDNA in Lymphoid Malignancies? Join us at the European Hematology Association (EHA) in the ESLHO Session on Saturday, 10th of June to learn more about current technologies applied for improving diagnsotics and patient care fields. #Lymphoma #LiquidBiopsy
To view or add a comment, sign in
-
Managing Partner and Client Services Director @ infill and Project Director @ memo inOncology / memo inHaematology
A new interview on memo inHaematology! Philipp Staber presents his opinion on functional drug testing and precision medicine in haematology. Stay tuned for more congress content from ASCO, EHA and ICML 2023 including a combined slide deck and SPECIAL ISSUE coming soon! #EHA2023 #17ICML #ASCO #hematology #precisionmedicine #medicaleducation #research
Watch Philipp Staber talk about recent haematooncological congress insights from 2023 EHA! In this interview on memoinoncology.com, Dr. Staber discusses: • What functional drug testing can achieve in the treatment of patients with hematologic diseases • What can be expected in the context of precision medicine for the management of patients with CLL • The most relevant current research topics and trials of EHA special working group “Precision Hematology” and its goals for the next 5 years Find more congress content from 2023 ASCO, EHA, and ICML on https://lnkd.in/dBqWaCM and wait for the combined slide deck coming soon! #EHA2023 #17ICML #ASCO #hematology #precisionmedicine
To view or add a comment, sign in
-
Current Opinion in Hematology is now on LinkedIn! We will be keeping our Current Opinion in Hematology community up to date with the editorials and review articles we are publishing on the latest and most exciting advances in the field of hematology. We will be spotlighting some of our latest publications and sharing with you what's new! The July issue is out now, and focuses on hematopoiesis. Use the following link to view the full table of contents online: https://lnkd.in/e5XnNjsS Here, you can also subscribe to receive journal alerts and information on upcoming issues by clicking on 'eTOC alerts' at the top of the page. Please share your comments in our group, we like to hear from you! #publishing #hematology
To view or add a comment, sign in
43,695 followers